Subsidize Dupixent Treatment for Severe Eczema Patients in Singapore


Subsidize Dupixent Treatment for Severe Eczema Patients in Singapore
The Issue
In Singapore, an estimated 20% of children and 11% of adults grapple with the challenges of eczema.
For over two decades, I have grappled with severe eczema, navigating a relentless cycle of flare-ups and persistent itching. Despite countless attempts with various treatments, creams, and medications, the emotional and physical toll of this condition has profoundly affected my daily life, professional pursuits, and personal relationships. The immeasurable impact on my quality of life underscores the urgent need for an accessible and effective solution.
Dupixent (dupilumab) has emerged as a revolutionary treatment, demonstrating significant efficacy in managing severe eczema symptoms. However, the prohibitive cost of this medication, approximately SG$2,000 per month (US$1500), poses a substantial barrier to access for many individuals, hindering their ability to effectively manage their condition. The financial strain associated with Dupixent is a considerable concern, especially considering that it is a lifelong treatment, limiting the options available to those in need.
Subsidizing Dupixent is crucial not only to alleviate the financial burden on eczema patients but also to enhance their overall quality of life. By making this medication more accessible, the government can actively contribute to the well-being of its citizens while simultaneously reducing long-term healthcare costs associated with untreated or poorly managed eczema cases.
We urge the Ministry of Health to consider subsidizing Dupixent treatment for severe eczema patients. This vital initiative has the potential to be the turning point for millions of individuals, transforming a life of constant suffering into one that mirrors normalcy.
By signing this petition, you are supporting the call for accessible and effective eczema treatment, ensuring that those in need can benefit from Dupixent without the burden of excessive financial constraints, particularly considering the lifelong nature of the treatment.
Together, let's make a difference in the lives of those battling severe eczema. Sign this petition and join the cause for a healthier and more equitable future.
558
The Issue
In Singapore, an estimated 20% of children and 11% of adults grapple with the challenges of eczema.
For over two decades, I have grappled with severe eczema, navigating a relentless cycle of flare-ups and persistent itching. Despite countless attempts with various treatments, creams, and medications, the emotional and physical toll of this condition has profoundly affected my daily life, professional pursuits, and personal relationships. The immeasurable impact on my quality of life underscores the urgent need for an accessible and effective solution.
Dupixent (dupilumab) has emerged as a revolutionary treatment, demonstrating significant efficacy in managing severe eczema symptoms. However, the prohibitive cost of this medication, approximately SG$2,000 per month (US$1500), poses a substantial barrier to access for many individuals, hindering their ability to effectively manage their condition. The financial strain associated with Dupixent is a considerable concern, especially considering that it is a lifelong treatment, limiting the options available to those in need.
Subsidizing Dupixent is crucial not only to alleviate the financial burden on eczema patients but also to enhance their overall quality of life. By making this medication more accessible, the government can actively contribute to the well-being of its citizens while simultaneously reducing long-term healthcare costs associated with untreated or poorly managed eczema cases.
We urge the Ministry of Health to consider subsidizing Dupixent treatment for severe eczema patients. This vital initiative has the potential to be the turning point for millions of individuals, transforming a life of constant suffering into one that mirrors normalcy.
By signing this petition, you are supporting the call for accessible and effective eczema treatment, ensuring that those in need can benefit from Dupixent without the burden of excessive financial constraints, particularly considering the lifelong nature of the treatment.
Together, let's make a difference in the lives of those battling severe eczema. Sign this petition and join the cause for a healthier and more equitable future.
558
The Decision Makers
Petition Updates
Share this petition
Petition created on 10 January 2024